Clinical Implications of Ki‐67 Index, Grade and Hormonal Changes in Pancreatic Neuroendocrine Tumors: Insights Into Tumor Heterogeneity Based on Primary and Secondary Lesions
Retrospective study shows increased tumor grade and Ki‐67 in metastatic pancreatic neuroendocrine tumors, indicating clinical implications for monitoring.
Key Points
Evaluate the clinical implications of Ki‐67 changes, tumor grade, and hormonal shifts in pancreatic neuroendocrine tumors.
Retrospective analysis of 114 patients with metastatic or recurrent pancreatic neuroendocrine tumors.
Comparison of paired specimens from 46 patients with synchronous metastases and recurrences.
Assessment of Ki‐67 index and tumor grade changes, alongside hormonal phenotype evaluations.
In metastases, mean Ki‐67 increased from 12.3% to 16.4%, with 22.2% showing a ≥ 10% increase.
In recurrences, Ki‐67 increased from 8.8% to 9.3%, with 15.8% showing a ≥ 10% increase.
Median progression‐free survival was 7.8 months in metastases versus 17.1 months in recurrences.
Median overall survival was longer in the recurrence group (124.8 vs. 32.5 months, p = 0.003).